IRIS
PANICHELLA, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.616
NA - Nord America 2.457
AS - Asia 2.334
SA - Sud America 657
AF - Africa 55
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.296
SG - Singapore 1.015
IT - Italia 925
RU - Federazione Russa 857
CN - Cina 550
BR - Brasile 548
VN - Vietnam 294
IE - Irlanda 150
DE - Germania 137
GB - Regno Unito 136
NL - Olanda 120
HK - Hong Kong 111
CA - Canada 104
TR - Turchia 61
IN - India 50
FI - Finlandia 48
BD - Bangladesh 47
FR - Francia 47
AR - Argentina 46
PL - Polonia 46
MX - Messico 42
PK - Pakistan 32
ID - Indonesia 31
IL - Israele 31
ES - Italia 27
SE - Svezia 27
ZA - Sudafrica 25
EC - Ecuador 24
AT - Austria 23
IQ - Iraq 23
JP - Giappone 23
CO - Colombia 13
UZ - Uzbekistan 13
CH - Svizzera 12
MA - Marocco 11
UA - Ucraina 11
LT - Lituania 10
AE - Emirati Arabi Uniti 9
BE - Belgio 9
PY - Paraguay 7
SA - Arabia Saudita 7
EG - Egitto 6
PE - Perù 6
RO - Romania 6
CL - Cile 5
KE - Kenya 5
KR - Corea 5
VE - Venezuela 5
DK - Danimarca 4
AL - Albania 3
AU - Australia 3
BY - Bielorussia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
JO - Giordania 3
KW - Kuwait 3
KZ - Kazakistan 3
NI - Nicaragua 3
UY - Uruguay 3
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
HN - Honduras 2
IR - Iran 2
LU - Lussemburgo 2
OM - Oman 2
TN - Tunisia 2
AD - Andorra 1
AO - Angola 1
BH - Bahrain 1
CG - Congo 1
CR - Costa Rica 1
CV - Capo Verde 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 8.120
Salva come PNG Salva come JPEG
Città #
Dallas 811
Singapore 548
Beijing 246
Ashburn 244
Moscow 159
Dublin 148
Hong Kong 107
Los Angeles 107
Ho Chi Minh City 92
Milan 89
Hanoi 67
New York 67
Rome 65
The Dalles 62
Pisa 61
Chandler 60
São Paulo 58
Hefei 54
Munich 52
Istanbul 42
Santa Clara 42
Florence 41
Warsaw 40
Montreal 35
London 34
Boardman 30
Beauharnois 29
Lucca 27
Brooklyn 25
Poplar 25
Tel Aviv 25
Rio de Janeiro 24
Boston 23
Chicago 23
Amsterdam 22
Bologna 22
Genoa 22
Stockholm 22
Tokyo 22
Frankfurt am Main 21
Lappeenranta 21
Orem 21
Naples 20
Nuremberg 20
Atlanta 19
Da Nang 19
Livorno 19
Brescia 18
Mexico City 18
Johannesburg 17
Denver 16
Buffalo 15
Chennai 15
Helsinki 15
Mumbai 15
Toronto 15
Turin 15
Belo Horizonte 14
Assago 12
Phoenix 12
Seattle 12
Turku 12
Washington 12
Manchester 11
Redondo Beach 11
Tashkent 11
Biên Hòa 10
Cambridge 10
Charlotte 10
Curitiba 10
Guayaquil 10
Haiphong 10
Lahore 10
Querétaro 10
San Mateo 10
Brasília 9
Dhaka 9
Houston 9
Portsmouth 9
Quito 9
San Jose 9
Buti 8
Ottawa 8
Palermo 8
Porto Alegre 8
Vienna 8
Zhengzhou 8
Ankara 7
Campinas 7
Cascina 7
Dongguan 7
Jakarta 7
Juiz de Fora 7
Paris 7
Bari 6
Brussels 6
Council Bluffs 6
Düsseldorf 6
Guangzhou 6
Padova 6
Totale 4.375
Salva come PNG Salva come JPEG
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 453
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 296
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 281
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 240
Screening the health status of people working in a university 219
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 209
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 205
Eligibility for vericiguat in a real‐world, contemporary heart failure population 191
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 188
Role of Imaging in Cardiomyopathies 181
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 176
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 176
Subclinical cardiac damage in cancer patients before chemotherapy 174
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population 173
Valvular heart disease in patients with cardiac amyloidosis 171
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 169
RNA-targeting and gene editing therapies for transthyretin amyloidosis 160
Sex-related differences in ventricular remodeling after myocardial infarction 157
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 155
Sex differences in transthyretin cardiac amyloidosis 152
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 150
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 150
Bridging Atrial and Ventricular Failure Through Biomarkers 150
Assessing cardiac mechanics through left ventricular haemodynamic forces 148
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 148
Pathophysiology of Cardiac Amyloidosis 147
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 145
The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population 144
Cardiac Amyloidosis: How Its Epidemiology is Changing 142
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 139
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 135
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 133
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 130
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review 129
Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat 124
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 121
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 118
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity 117
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 114
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 112
Dissecting the heart failure phenotype through phenomics 111
High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis 109
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 108
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis 107
Pirfenidone as a novel cardiac protective treatment 100
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 99
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 92
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 92
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 91
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 83
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up 81
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 80
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management 79
Metabolomics to predict heart failure development: A new frontier? 76
null 29
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy 28
Totale 8.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.088
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.088
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202266 0 0 0 5 7 7 10 17 7 6 2 5
2022/2023367 5 28 10 21 44 40 14 47 109 10 27 12
2023/2024333 13 11 63 36 7 25 27 13 15 26 28 69
2024/20252.806 71 68 134 108 184 154 383 539 286 175 378 326
2025/20264.615 441 1.077 771 1.145 801 380 0 0 0 0 0 0
Totale 8.187